Study to Investigate the Safety, Tolerability, Mechanism of Action and Exploratory Clinical Efficacy of Repeat Dose HF1020 in Patients with Moderate to Severe Psoriasis
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2016
At a glance
- Drugs HF 1020 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2014 Status changed from suspended to completed as reported by United Kingdom Clinical Research Network record.
- 05 Oct 2013 Status changed from recruiting to suspended as reported by United Kingdom Clinical Research Network.
- 08 Jun 2013 New trial record